# A Study of IMR-687 in Healthy Adult Volunteers

> **NCT02998450** · PHASE1 · COMPLETED · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle-Cell; Hb-SC
- Sickle Beta 0 Thalassemia

## Interventions

- **DRUG:** IMR-687
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT02998450
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2017-07-08
- **Final completion:** 2017-07-08
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998450, "A Study of IMR-687 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02998450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*